Compare Globus Medical Inc. Class A Common Stock (GMED) vs HubSpot Inc (HUBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs HubSpot Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while HubSpot Inc trades at $226.25 (market cap $11.03B). The key difference: Globus Medical Inc. Class A Common Stock and HubSpot Inc are close in size by market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, HubSpot Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and HubSpot Inc for 78 Days on average.
| GMED | HUBS | |
|---|---|---|
Market Cap | $10.25B | $11.03B |
Volume | 1,108,124 | 784,639 |
Sector | Health | Technology |
52-Week High | $96.82 | $494.58 |
52-Week Low | $58.33 | $170.39 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $9.76B | $9.93B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
HubSpot (HUBS) trades at $226.23, up 1.28% today, with a neutral technical signal and strong fundamental growth. The stock has beaten earnings estimates for the last three quarters, with revenue growing from $1.7B in 2022 to $3.1B in 2025. Recent news highlights an AI-focused strategy and partnership with OpenAI, aiming to boost margins and customer outcomes.
The outlook is positive with 55% analyst buy ratings and a $244.09 consensus price target, suggesting 8% upside. Key risks include high valuation multiples and competitive pressures in the SaaS space. Cash flow growth and institutional accumulation support the bullish case, but investors should monitor execution of AI initiatives and margin targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
